Trial Profile

Phase 2 Study of ADXS11-001 in Subjects With Persistent/Recurrent, Loco-Regional or Metastatic Squamous Cell Carcinoma of the Anorectal Canal

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 22 Mar 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Axalimogene filolisbac (Primary)
Indications Anal cancer; Rectal cancer; Squamous cell cancer
Focus Therapeutic Use
Acronyms FAWCETT
Sponsors Advaxis

Most Recent Events

22 Mar 2023 This study protocol has been amended as primary endpoint (Number of subjects with adverse events) has been removed and trial focus has been shifted to TU only from TU and AR.
11 Mar 2020 Status changed from active, no longer recruiting to completed.
04 Mar 2019 Planned End Date changed from 1 Mar 2022 to 1 May 2019.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com